Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, US

Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that specializes in small molecule drug technologies to bring new medicines to patients. The company s most-advanced drug candidate, IPI-504, is a proprietary, targeted cancer therapy that preferentially induces the death of cancer cells through the inhibition of the heat shock protein 90 complex. In preclinical animal studies of a wide variety of hematological malignancies and solid tumors, IPI-504 has demonstrated utility as both a single agent and in combination with other therapies. Infinity Pharmaceuticals owns all rights to the IPI-504 and commenced Phase I clinical trials in July 2005. The company also has an advanced drug candidate in IPI-609, another proprietary small molecule that operates through inhibition of the Hedgehog cell signaling pathway. Infinity also owns all rights to IPI-609. Since Infinity was founded in 2001, the company has raised more than $130 million from corporate partnerships and premier venture capitalists.

Navy Federal Credit Union

Atm